ArticleMedicine2026
Global burden of disease for gastric cancer from 1990 to 2023 and projections of the burden to 2035.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gastric cancer (GC) remains a major global health challenge, contributing substantially to cancer incidence and mortality worldwide. This study aimed to evaluate the worldwide disease burden and evolving trends of GC utilizing the Global Burden of Disease 2023 database, intending to offer a robust scientific foundation for public health policy. Utilizing pertinent information from the Global Burden of Disease 2023 database, we calculated the estimated annual percentage change to measure temporal trends. We applied age-period-cohort models to analyze the impacts of time periods and cohorts from 1990 to 2023. Additionally, we explored the correlation between the burden of GC and the socio-demographic index through frontier analysis and health inequality evaluation while forecasting future trends utilizing Bayesian age-period-cohort models. From 1990 to 2023, the global cases of GC rose by 20.04%, reaching 1262,000; the total number of deaths increased from 912,483 to 934,795; however, cancer-related disability-adjusted life years (DALYs) declined by 8.85% compared to 1990. The age-standardized incidence rate, age-standardized mortality rate, and age-standardized DALY rate of GC have generally demonstrated a downward trend since 1990. The disease burden is notably greater in males than in females. Bayesian age-period-cohort projections indicate that by 2035, GC incidence is anticipated to reach 1,159,745, while the expected numbers of deaths and DALYs are forecasted to decline to 667,145 and 15,783,072, respectively; additionally, the impact of GC in older age demographics is projected to increase significantly. Although the age-standardized incidence, mortality, and disability rates of GC have declined globally from 1990 to 2023, the absolute number of incident cases, deaths, and DALYs remains substantial, indicating a persistent global health burden. Future prevention strategies should consider differences in demographic structure, socioeconomic development, and regional disease patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.